10-Q: Inspire Medical Systems Reports Q2 2026 Results, Revenue Declines

Inspire Medical Systems announced Q2 2026 results showing a revenue decrease driven by U.S. market challenges, while also detailing ongoing legal proceedings and a new strategic growth plan.

Summary

• Inspire Medical Systems reported a revenue decrease of 7.6% for the three months ended June 30, 2026, to $200.6 million, and a 3.2% decrease for the six months ended June 30, 2026, to $405.2 million.
• The decline in revenue is primarily attributed to adverse impacts from coding and reimbursement challenges in the U.S. market, as well as delays due to the WISeR program.
• Gross margin improved to 85.5% for the quarter and 86.0% for the six months, attributed to a higher sales mix of the Inspire V system.
• Operating loss for the quarter was $0.5 million, an improvement from $3.3 million in the prior year period. For the six months, the operating loss was $1.6 million, an improvement from $4.8 million.
• Net earnings for the quarter were $0.3 million, a significant improvement from a net loss of $3.6 million in the prior year. However, the six-month period resulted in a net loss of $11.0 million, compared to a net loss of $0.6 million in the prior year.
• The company announced a strategic growth plan called 'Project Horizon' aimed at accelerating revenue growth through resource alignment, organizational streamlining, and supply chain optimization, expecting $20-$25 million in pre-tax restructuring charges.
• Significant legal proceedings are ongoing, including securities class actions and patent infringement lawsuits against and by Nyxoah SA.
• Cash and cash equivalents increased to $127.8 million as of June 30, 2026, from $104.8 million as of December 31, 2025.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as cautiously negative due to declining revenues, ongoing legal challenges, and the impact of reimbursement uncertainties, despite some operational improvements.

Positives

• Gross margin improved to 85.5% for Q2 2026 and 86.0% for the first six months of 2026, driven by a higher sales mix of the Inspire V system.
• Operating loss narrowed significantly to $0.5 million for Q2 2026 from $3.3 million in Q2 2025, and to $1.6 million for the first six months of 2026 from $4.8 million in the prior year.
• Net earnings for Q2 2026 were $0.3 million, a substantial improvement from a net loss of $3.6 million in Q2 2025.
• Net cash provided by operating activities was $36.1 million for the first six months of 2026, a significant increase from $4.0 million used in the prior year period, primarily due to improved working capital.
• Cash and cash equivalents increased to $127.8 million as of June 30, 2026, providing a solid liquidity position.

Negatives

• Revenue decreased by 7.6% to $200.6 million for Q2 2026 and by 3.2% to $405.2 million for the first six months of 2026.
• U.S. revenue declined by 9.6% in Q2 2026 and 4.5% in the first six months of 2026, primarily due to adverse impacts of coding and reimbursement challenges and the WISeR program.
• The company anticipates continued adverse impacts on revenue from coding and reimbursement uncertainty and the WISeR program throughout the remainder of 2026.
• Net loss for the first six months of 2026 was $11.0 million, compared to a net loss of $0.6 million in the prior year period.
• The effective tax rate increased significantly to 89.9% for Q2 2026 and 299.2% for the first six months of 2026, primarily due to tax shortfalls related to stock-based compensation.
• The company is facing multiple significant legal proceedings, including securities class actions and patent infringement lawsuits.

Risks

• Ongoing uncertainty and changes related to appropriate coding and reimbursement for Inspire V therapy from CMS, Medicare Administrative Contractors, and other payors are adversely impacting revenue.
• The WISeR program, requiring prior authorization for Medicare cases in six pilot states, caused delays and adversely impacted revenue in the first half of 2026, with continued impact expected.
• The increasing prevalence and adoption of GLP-1 drugs for OSA treatment are currently believed to be adversely impacting revenue in the short-term.
• The strategic growth plan, Project Horizon, may result in unintended consequences such as loss of institutional knowledge, employee attrition beyond targets, decreased morale, and reputational harm.
• The company is involved in multiple legal proceedings, including securities class actions and patent infringement lawsuits, which could result in significant financial and managerial resource expenditure and potential adverse effects.
• Product liability claims and warranty claims are a risk.
• Failure of key information technology systems, processes, or sites, or damage to or inability to access physical facilities, could disrupt operations.
• Risks related to product liability claims and warranty claims.

Future Outlook

The company anticipates continued adverse impacts on revenue during the remainder of 2026 due to coding and reimbursement uncertainty and the WISeR program, though to a lesser extent than in the first half of the year. The strategic growth plan, Project Horizon, is expected to create approximately $30 million of annualized growth investment capacity.

Management Comments

• The company is actively engaging with relevant stakeholders regarding reimbursement uncertainty affecting Inspire V and is providing support to minimize potential delays and continue patient access to therapy.
• Inspire is seeking a long-term solution, including the creation of a separate CPT code for its therapy.
• The company believes that with the availability of GLP-1s to treat OSA, the number of patients seeking diagnosis and treatment for OSA is increasing, which may lead to an increase in eligible patients for Inspire therapy in the long-term.
• Management expects to incur $20 million to $25 million of pre-tax restructuring charges in connection with Project Horizon, with the majority of actions completed in Q3 2026 and all actions substantially complete by the end of 2026.

Industry Context

StockSavvy.ai notes that the declining revenue and ongoing reimbursement challenges for Inspire Medical Systems are occurring within a broader context of evolving treatment paradigms for Obstructive Sleep Apnea (OSA), including the rise of GLP-1 drugs. Competitors like Nyxoah are also engaged in patent litigation, highlighting the competitive and litigious nature of the medical device sector.

Comparison to Industry Standards

• The company's revenue decline contrasts with the general growth expected in the medical device sector, particularly for innovative treatments.
• The gross margin of 85.5% is strong and generally above industry averages for medical device companies, indicating efficient production of the Inspire V system.
• The significant operating loss, though narrowing, is not uncommon for companies in the growth and commercialization phase of novel medical technologies, but the revenue decline poses a challenge to achieving profitability.
• The ongoing legal battles with Nyxoah SA are typical of the competitive landscape in the medical device industry, where intellectual property is a key differentiator.

Legal Proceedings

• Securities class action lawsuit filed by City of Pontiac Reestablished General Employees Retirement System (administratively closed without prejudice).
• Securities class action lawsuit filed by Indiana Public Retirement System, now transferred to Minnesota and amended complaint filed.
• Stockholder derivative lawsuits filed by Korte, Davis, and Ahlberg, which have been consolidated and stayed.
• Civil investigative demand (CID) from the Department of Justice U.S. Attorneys Office for the District of Minnesota regarding False Claims Act investigation.
• Qui tam lawsuit filed by former employee Patrick Collins under the False Claims Act, which has been unsealed and is being defended.
• Lawsuit filed by Inspire against Nyxoah SA for patent infringement, with Nyxoah denying infringement and filing counterclaims.
• Lawsuit filed by Nyxoah SA against Inspire alleging patent infringement.
• Lawsuit filed by Nyxoah against Inspire and its European subsidiary in the Unified Patent Court alleging patent infringement.

Stakeholder Impact

• Shareholders: Declining revenue and ongoing legal challenges may negatively impact share price and investor confidence. The strategic growth plan aims to accelerate revenue growth, which could benefit shareholders long-term.
• Customers (Hospitals and ASCs): Coding and reimbursement challenges, along with WISeR program delays, may create administrative burdens and impact adoption rates.
• Patients: Continued access to therapy is a focus, but reimbursement uncertainties and potential delays could affect patient access.
• Employees: Project Horizon includes streamlining the organization and a workforce reduction, which could impact morale and lead to loss of institutional knowledge.

Next Steps

• Complete the majority of actions related to Project Horizon in the third quarter of 2026 and all actions substantially by the end of 2026.
• Continue to engage with stakeholders to minimize reimbursement uncertainty and seek a long-term solution, including the creation of a separate CPT code.
• Provide proactive education and assistance to field teams, customers, and physicians to support patient access to therapy.
• Continue to invest in revenue growth initiatives funded by the capacity created by Project Horizon.
• Vigorously defend against ongoing legal actions, including securities class actions and patent infringement lawsuits.

Key Dates

Recommendation

The company shows operational improvements in gross margin and narrowed operating losses, but the significant revenue decline, ongoing reimbursement and coding challenges, and extensive legal proceedings present substantial headwinds. While the strategic growth plan offers a path forward, the near-term outlook remains uncertain, warranting a hold position until revenue trends stabilize and legal risks are resolved.

Keywords

Obstructive Sleep Apnea, Neurostimulation, Medical Device, Revenue Decline, Reimbursement Challenges, Project Horizon, Securities Class Action, Patent Litigation